Loading
Samantha Du founded Zai Lab in 2014 to license Western cancer drugs for China, bringing niraparib, zanidatamab and Tumour Treating Fields to Chinese patients years earlier than they would otherwise have arrived.
Samantha Du (Du Ying) is Founder, Chairperson and CEO of Zai Lab. Formerly at Pfizer and a co-founder of Hutchmed's drug discovery arm, she founded Zai Lab in 2014 to license Western cancer drugs for China, bringing niraparib, zanidatamab and Tumour Treating Fields to Chinese patients years earlier than they would otherwise have arrived. The in-licensing model she created was copied by many Chinese biotechs, and she listed the company on Nasdaq in 2017 and in Hong Kong in 2020. Under her leadership Zai Lab has since built internal DLL3 and LRRC15 antibody-drug conjugate programmes alongside its commercialisation work.
Shares Hutchmed and the tag china.
Shares Hutchmed and the tag china.
Shares Hutchmed and the tag china.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/